Continue to site >
Trending ETFs

Name

As of 07/11/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$25.34

$3.54 M

0.05%

$0.01

0.47%

Vitals

YTD Return

-3.4%

1 yr return

4.8%

3 Yr Avg Return

N/A

5 Yr Avg Return

N/A

Net Assets

$3.54 M

Holdings in Top 10

48.0%

52 WEEK LOW AND HIGH

$24.5
$19.08
$26.77

Expenses

OPERATING FEES

Expense Ratio 0.47%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 07/11/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$25.34

$3.54 M

0.05%

$0.01

0.47%

IBRN - Profile

Distributions

  • YTD Total Return -3.4%
  • 3 Yr Annualized Total Return N/A
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio N/A
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    iShares Neuroscience and Healthcare ETF
  • Fund Family Name
    BlackRock-advised Funds
  • Inception Date
    Aug 26, 2022
  • Shares Outstanding
    N/A
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US

Fund Description

The Fund seeks to track the investment results of the NYSE® FactSet® Global Neuro Biopharma and MedTech Index (the Underlying Index), which measures the performance of equity securities of companies that are involved in the research, development or manufacturing of neurology biopharmaceuticals or neurological devices, as determined by ICE Data Indices, LLC or its affiliates (the Index Provider or IDI).
To be eligible for the Underlying Index, an equity security must (i) be listed in one of 44 developed and emerging market countries or regions, (ii) have a float-adjusted market capitalization of at least $100 million and (iii) have a three-month average daily trading value ADTV) of at least $1 million. Existing constituents may remain in the Underlying Index with a float-adjusted market capitalization of at least $75
million and a three-month ADTV of at least $750,000 at each index reconstitution and rebalance.
The Underlying Index is composed of securities that are classified within one of two sub-industries defined by the FactSet Revere Business Industry Classification System (RBICS): Neurology Biopharmaceuticals and Neurology Devices. For a company to be included in either sub-industry, the sub-industry must represent at least 50% of the company’s annual revenues or, for pre-revenue companies, the company’s primary business as indicated by its product pipeline, each as determined by the Index Provider. The methodology does not require that at least one company from each of the sub-industries be included in the Underlying Index. Constituents may also operate business lines that generate revenue in other industries. The Index Provider seeks to exclude companies whose business description, trade names or supply chain relationships indicate an involvement with psychedelics or cannabis, as determined by the Index Provider based on an analysis using FactSet keyword data.
The Underlying Index is reviewed and reconstituted in March and September and rebalanced quarterly. Constituent weights of the Underlying Index are determined according to float-adjusted market capitalization, and individual constituents are capped at 4% of the Underlying Index at each index reconstitution and rebalance.
As of July 31, 2023, a significant portion of the Underlying Index is represented
by securities of companies in the healthcare, neurology biopharmaceuticals and neurology devices industries or sectors. As of July 31, 2023, the Underlying Index consisted of securities from the following countries or regions: Australia, China, South Korea, Sweden, Switzerland, and the U.S. The Underlying Index includes large-, mid- and small-capitalization companies, and its components are likely to change over time.
BFA uses an indexing approach to try to achieve the Fund’s investment objective. Unlike many investment companies, the Fund does not try to beat the index it tracks and does not seek temporary defensive positions when markets decline or appear overvalued.
Indexing may eliminate the chance that the Fund will substantially outperform the Underlying Index but also may reduce some of the risks of active management, such as poor security selection. Indexing seeks to achieve lower costs and better after-tax performance by aiming to keep portfolio turnover low in comparison to actively managed investment companies.
BFA uses a representative sampling indexing strategy to manage the Fund. Representative sampling is an indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to that of an applicable underlying index. The securities selected are expected to have, in the aggregate, investment characteristics (based on factors such as market capitalization and industry weightings), fundamental characteristics (such as return variability and yield) and liquidity
measures similar to those of an applicable underlying index. The Fund may or may not hold all of the securities in the Underlying Index.
The Fund generally will invest at least 80% of its assets in the component securities of its Underlying Index and in investments that have economic characteristics that are substantially identical to the component securities of its Underlying Index (i.e., depositary receipts representing securities of the Underlying Index) and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, including shares of money market funds advised by BFA or its affiliates, as well as in securities not included in the Underlying Index, but which BFA believes will help the Fund track the Underlying Index. Cash and cash equivalent investments associated with a derivative position will be treated as part of that position for the purposes of calculating the percentage of investments included in the Underlying Index. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund.
The Fund may lend securities representing up to one-third of the value of the Fund's total assets (including the value of any collateral received).
The Underlying Index is owned, maintained and administered by the Index Provider, which isindependent of the Fund and BFA. The Index Provider determines the composition and relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
Industry Concentration Policy. The Fund will concentrate its investments
i.e., hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. For purposes of this limitation, securities of the U.S. government (including its agencies and instrumentalities) and repurchase agreements collateralized by U.S. government securities are not considered to be issued by members of any industry.
Read More

IBRN - Performance

Return Ranking - Trailing

Period IBRN Return Category Return Low Category Return High Rank in Category (%)
YTD -3.4% N/A N/A N/A
1 Yr 4.8% N/A N/A N/A
3 Yr N/A* N/A N/A N/A
5 Yr N/A* N/A N/A N/A
10 Yr N/A* N/A N/A N/A

* Annualized

Return Ranking - Calendar

Period IBRN Return Category Return Low Category Return High Rank in Category (%)
2023 0.9% N/A N/A N/A
2022 N/A N/A N/A N/A
2021 N/A N/A N/A N/A
2020 N/A N/A N/A N/A
2019 N/A N/A N/A N/A

Total Return Ranking - Trailing

Period IBRN Return Category Return Low Category Return High Rank in Category (%)
YTD -3.4% N/A N/A N/A
1 Yr 4.8% N/A N/A N/A
3 Yr N/A* N/A N/A N/A
5 Yr N/A* N/A N/A N/A
10 Yr N/A* N/A N/A N/A

* Annualized

Total Return Ranking - Calendar

Period IBRN Return Category Return Low Category Return High Rank in Category (%)
2023 0.9% N/A N/A N/A
2022 N/A N/A N/A N/A
2021 N/A N/A N/A N/A
2020 N/A N/A N/A N/A
2019 N/A N/A N/A N/A

IBRN - Holdings

Concentration Analysis

IBRN Category Low Category High IBRN % Rank
Net Assets 3.54 M N/A N/A N/A
Number of Holdings 55 N/A N/A N/A
Net Assets in Top 10 1.69 M N/A N/A N/A
Weighting of Top 10 47.98% N/A N/A N/A

Top 10 Holdings

  1. BlackRock Cash Funds: Institutional, SL Agency Shares 6.59%
  2. Neurocrine Biosciences Inc 4.89%
  3. Cerevel Therapeutics Holdings Inc 4.86%
  4. PTC Therapeutics Inc 4.70%
  5. Intra-Cellular Therapies Inc 4.69%
  6. Sarepta Therapeutics Inc 4.60%
  7. Axonics Inc 4.59%
  8. Biogen Inc 4.54%
  9. Argenx SE 4.46%
  10. Xenon Pharmaceuticals Inc 4.05%

Asset Allocation

Weighting Return Low Return High IBRN % Rank
Stocks
99.83% N/A N/A N/A
Cash
6.59% N/A N/A N/A
Preferred Stocks
0.00% N/A N/A N/A
Other
0.00% N/A N/A N/A
Convertible Bonds
0.00% N/A N/A N/A
Bonds
0.00% N/A N/A N/A

Stock Sector Breakdown

Weighting Return Low Return High IBRN % Rank
Utilities
0.00% N/A N/A N/A
Technology
0.00% N/A N/A N/A
Real Estate
0.00% N/A N/A N/A
Industrials
0.00% N/A N/A N/A
Healthcare
0.00% N/A N/A N/A
Financial Services
0.00% N/A N/A N/A
Energy
0.00% N/A N/A N/A
Communication Services
0.00% N/A N/A N/A
Consumer Defense
0.00% N/A N/A N/A
Consumer Cyclical
0.00% N/A N/A N/A
Basic Materials
0.00% N/A N/A N/A

Stock Geographic Breakdown

Weighting Return Low Return High IBRN % Rank
US
88.24% N/A N/A N/A
Non US
11.59% N/A N/A N/A

IBRN - Expenses

Operational Fees

IBRN Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.47% N/A N/A N/A
Management Fee 0.47% N/A N/A N/A
12b-1 Fee N/A N/A N/A N/A
Administrative Fee N/A N/A N/A N/A

Sales Fees

IBRN Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A N/A N/A N/A
Deferred Load N/A N/A N/A N/A

Trading Fees

IBRN Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A N/A N/A N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IBRN Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A N/A N/A N/A

IBRN - Distributions

Dividend Yield Analysis

IBRN Category Low Category High IBRN % Rank
Dividend Yield 0.05% N/A N/A N/A

Dividend Distribution Analysis

IBRN Category Low Category High Category Mod
Dividend Distribution Frequency Annual

Net Income Ratio Analysis

IBRN Category Low Category High IBRN % Rank
Net Income Ratio N/A N/A N/A N/A

Capital Gain Distribution Analysis

IBRN Category Low Category High Capital Mode
Capital Gain Distribution Frequency

Distributions History

View More +

IBRN - Fund Manager Analysis

Tenure Analysis

Category Low Category High Category Average Category Mode
N/A N/A N/A N/A